Targeting the Correct Population for Trials: A Post‐hoc Analysis of Trial of Solanezumab for Mild Dementia Due to Alzheimer’s disease.

Up to 50% of placebo treated participants in AD clinical trials do not show clinically meaningful cognitive decline (CMCD) over the course of study. Inclusion of these individuals makes it more difficult to demonstrate the benefits of treatments intended to slow cognitive decline. Here, we used data from the trial of solanezumab for mild AD (EXPEDITION3) to investigate effectiveness of predictive models for enrichment of trials.